On May 6, 2024 Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, reported the appointment of Marc Becker as the company’s Chief Financial Officer and Chief Operating Officer (Press release, Ratio Therapeutics, MAY 6, 2024, View Source [SID1234642684]). This appointment will reinforce Ratio’s financial and operational leadership by bringing significant experience in biotech and pharma to guide growth strategies and ensure continued success.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are honored to welcome Marc to the Ratio team," commented Dr. Jack Hoppin, Chairman and Chief Executive Officer of Ratio. "Building on the recent expansion of our leadership team and board, the appointment of our new CFO/COO is essential as we navigate the dynamic and rapidly evolving radiopharmaceutical space, which is currently experiencing significant growth and activity. Marc’s experience in financial management and strategic planning makes him a valuable asset as we continue to grow and develop our pipeline of radiopharmaceuticals."
"It’s a privilege to become part of Ratio’s team during this critical juncture, especially with the escalating momentum surrounding the development of targeted radiopharmaceuticals within our industry," said Marc Becker, Chief Financial Officer and Chief Operating Officer of Ratio. "I look forward to applying my financial expertise and knowledge of the biopharmaceutical sector to help shape Ratio’s strategic direction and ensure our growth is robust and sustainable."
Mr. Becker brings 20+ years of experience in biotech and pharma to his role as CFO/COO at Ratio. With a proven track record of success in strategic planning, finance transactions, and operational scaling, he will play a crucial role in driving forward the company’s vision and business objectives. Prior to his most recent position as CFO, Growth Companies, at Flagship, Mr. Becker served as CFO for Concert Pharmaceuticals, Inc., where he raised several rounds of financing and led a successful M&A process culminating in a sale to Sun Pharma in March 2023. He also previously served as CFO at CRISPR Therapeutics, where he led a successful IPO. Additionally, he held the position of CFO and Senior Vice President at rEVO Biologics and served as Vice President at Genzyme Corporation. Mr. Becker holds a BS in Accounting from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.